EUVIMEDEUVIMED entdecken
Crossref

Erenumab and Galcanezumab for Chronic Migraine Refractory to OnabotulinumtoxinA: A Real-World Comparative Study

Sara Martín-Yeves, Ana Colón-López de Dicastillo iD, Javier Riancho iD, José Ramón Sánchez-de la Torre iD, Yésica Jiménez-López iD, Sonia Setién iD, Mercedes Misiego-Peral, Daniel Gallo, Patricia Zunzunegui-Arroyo, Arancha Sainz-Pelayo iD, Manuel Delgado-Alvarado iD

Annals of Pharmacotherapy · 14.04.2026

DOI: 10.1177/10600280261429460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 14.04.2026. Verfasst von Sara Martín-Yeves und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital Sierrallana, Torrelavega, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Research Intensification Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistant chronic migraine remains a major therapeutic challenge, particularly in patients who continue to be symptomatic despite OnabotulinumtoxinA. Anti–calcitonin gene–related peptide (CGRP) monoclonal antibodies may provide effective preventive options, but comparative real-world data and quantification of acute medication reduction remain limited.

Objective

To compare the real-world effectiveness of erenumab versus galcanezumab in patients with chronic migraine refractory to OnabotulinumtoxinA and to evaluate changes in acute medication use.

Methods

We conducted a retrospective observational study of consecutive patients treated at a neurology outpatient clinic in Cantabria, Spain (ethics approval code 2022.204). Monthly migraine days (MMD) were recorded at baseline and during 3 follow-up visits. Acute medication use (monthly units of triptans and NSAIDs) was obtained from the electronic prescription dispensing system for the 6 months before and after treatment initiation. Changes in MMD were analyzed using a linear mixed-effects model. Acute medication changes were analyzed using a 2-way repeated-measures ANOVA (time pre/post × treatment group).

Results

Forty-five patients were included (erenumab n = 24; galcanezumab n = 21). Mean MMD decreased from 20.1 ± 7.9 at baseline to 8.0 ± 6.6, 8.1 ± 7.3, and 6.4 ± 7.7 at visits 1–3 ( P < 0.001), with no between-group differences (group P = 0.576; interaction P = 0.524). Across visits, ≥50% responder rates ranged from 57.1% to 85.0% and ≥75% responder rates from 35.0% to 57.1%, with no differences between treatments (all P > 0.05). Triptan use decreased significantly over time ( P = 0.033), whereas NSAID use did not ( P = 0.344). Conclusion and relevance: In patients with chronic migraine refractory to OnabotulinumtoxinA, erenumab and galcanezumab produced comparable and sustained reductions in migraine frequency, with high responder rates. Treatment was associated with reduced triptan use, supporting the clinical relevance of anti-CGRP monoclonal antibodies in this population.

Schlagwörter

Stichwörter der Autor:innen

CGRP monoclonal antibodieschronic migraineerenumabgalcanezumab

Autor:innen und Institutionen

  • Department of Internal Medicine, Hospital Sierrallana, Torrelavega, Spain.
  • Department of Pharmacy, Hospital Sierrallana, Torrelavega, Spain.
  • Department of Neurology, Hospital Sierrallana, Torrelavega, Spain.
  • Marqués de Valdecilla University Hospital Health Research Institute, IDIVAL, Santander, Spain.
  • Centre for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain.

ORCID-Profile: Ana Colón-López de Dicastillo, Javier Riancho, José Ramón Sánchez-de la Torre, Yésica Jiménez-López, Sonia Setién, Arancha Sainz-Pelayo, Manuel Delgado-Alvarado

Förderung

  • Instituto de Salud Carlos III
  • Research Intensification Grant

Zitieren

APA

Martín-Yeves, S., Colón-López de Dicastillo, A., Riancho, J., Sánchez-de la Torre, J. R., Jiménez-López, Y., Setién, S., Misiego-Peral, M., Gallo, D., Zunzunegui-Arroyo, P., Sainz-Pelayo, A., & Delgado-Alvarado, M. (2026). Erenumab and Galcanezumab for Chronic Migraine Refractory to OnabotulinumtoxinA: A Real-World Comparative Study. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261429460

Vancouver

Martín-Yeves S, Colón-López de Dicastillo A, Riancho J, Sánchez-de la Torre JR, Jiménez-López Y, Setién S, et al. Erenumab and Galcanezumab for Chronic Migraine Refractory to OnabotulinumtoxinA: A Real-World Comparative Study. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261429460

BibTeX
@article{MartnYeves2026,
  author = {Martín-Yeves, Sara and Colón-López de Dicastillo, Ana and Riancho, Javier and Sánchez-de la Torre, José Ramón and Jiménez-López, Yésica and Setién, Sonia and Misiego-Peral, Mercedes and Gallo, Daniel and Zunzunegui-Arroyo, Patricia and Sainz-Pelayo, Arancha and Delgado-Alvarado, Manuel},
  title = {Erenumab and Galcanezumab for Chronic Migraine Refractory to OnabotulinumtoxinA: A Real-World Comparative Study},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  doi = {10.1177/10600280261429460}
}
Kostenlos starten →